Author:
Tabernero J.,Salazar R.,Casado E.,Martinelli E.,Gómez P.,Baselga J.
Reference48 articles.
1. Targeting the epidermal growth factor receptor for cancer therapy;Mendelsohn;J Clin Oncol,2002
2. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma: implications for a standardized scoring system;Goldstein;Cancer,2001
3. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR);Saltz;Proc Am Soc Clin Oncol,2001
4. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC);Cunningham;Proc Am Soc Clin Oncol,2003
5. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67;Hemming;J Surg Oncol,1992
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献